Commentary & Perspectives
Is Standard of Care Optimal for the Individual Patient?
-
By
-
April 15, 2026
-
8 min
By
April 15, 2026
In an Australian phase IB to II study (PRINCE) reported in The Lancet Oncology, Sandhu et al found that the combination of lutetium-177–labeled PSMA-617 (LuPSMA-617) and pembrolizumab was active in pa...
April 15, 2026
Novogaia’s transformer-based model converts untargeted mass spectra into structural predictions for early-stage drug discovery
by Henry Thomas
April 15, 2026
Advances in imaging, AI, and single-cell analysis reveal hidden chemistry in art, biology, and the environment
April 15, 2026